Hering S, Nieto A, Marschner S, Hofmaier J, Schmidt-Hegemann NS, da Silva Mendes V, Landry G, Niyazi M, Manapov F, Belka C, Corradini S, Eze C (2024)
Publication Type: Journal article
Publication year: 2024
Book Volume: 45
Article Number: 100736
DOI: 10.1016/j.ctro.2024.100736
Background: The aim of this prospective observational study was to evaluate the dosimetry benefits, changes in pulmonary function, and clinical outcome of online adaptive MR-guided SBRT. Methods: From 11/2020–07/2022, 45 consecutive patients with 59 lesions underwent multi-fraction SBRT (3–8 fractions) at our institution. Patients were eligible if they had biopsy-proven NSCLC or lung cancer/metastases diagnosed via clinical imaging. Endpoints were local control (LC) and overall survival (OS). We evaluated PTV/GTV dose coverage, organs at risk exposure, and changes in pulmonary function (PF). Acute toxicity was classified per the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0. Results: The median PTV was 14.4 cm3 (range: 3.4 – 96.5 cm3). In total 195/215 (91%) plans were reoptimised. In the reoptimised vs. predicted plans, PTV coverage by the prescribed dose increased in 94.6% of all fractions with a median increase in PTV V
APA:
Hering, S., Nieto, A., Marschner, S., Hofmaier, J., Schmidt-Hegemann, N.S., da Silva Mendes, V.,... Eze, C. (2024). The role of online MR-guided multi-fraction stereotactic ablative radiotherapy in lung tumours. Clinical and Translational Radiation Oncology, 45. https://doi.org/10.1016/j.ctro.2024.100736
MLA:
Hering, Svenja, et al. "The role of online MR-guided multi-fraction stereotactic ablative radiotherapy in lung tumours." Clinical and Translational Radiation Oncology 45 (2024).
BibTeX: Download